ACP
ESPR

Acuta Capital Partners’s Esperion Therapeutics ESPR Stock Holding History

Acuta Capital Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-25,000
Closed -$980K – 36
2018
Q2 		$980K Buy
+25,000
New +$1.26M 0.17% 47

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acuta Capital Partners's ESPR Position: Q4 2022 in Review

Acuta Capital Partners sold out of Esperion Therapeutics (ESPR) in Q4 2022, closing a stake of 30,000 shares — an estimated $201K sold.

Acuta Capital Partners first reported a position in ESPR in Q3 2022 and held it in 1 quarter. The position peaked at $201K in Q3 2022. 165 funds tracked by Wall St. Rank hold ESPR as of Q4 2022.

  • Acuta Capital Partners reported no remaining Esperion Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 30,000 Esperion Therapeutics shares in Q4 2022, an estimated $201K.
  • Acuta Capital Partners first reported a position in Esperion Therapeutics in Q3 2022 and held it in 1 quarter.
  • Acuta Capital Partners's Esperion Therapeutics position peaked at $201K in Q3 2022.
  • 165 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.